These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36523777)

  • 1. The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients.
    Zhao C; Guo Y; Wang Y; Wang L; Yu L; Liang Y; Zhai Z; Tang L
    Front Med (Lausanne); 2022; 9():1055330. PubMed ID: 36523777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.
    Guo Y; Ren M; Wang T; Wang Y; Pu T; Li X; Yu L; Wang L; Liu P; Tang L
    Front Cardiovasc Med; 2022; 9():955780. PubMed ID: 36440034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on the Efficacy of Sacubitril/Valsartan in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Peritoneal Dialysis.
    Sheng Y; Ma X; Liu Y; Yang X; Sun F
    Cardiology; 2023; 148(5):385-394. PubMed ID: 37253340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease.
    Ge T; Yang Y; Zhao Y
    Perfusion; 2023 Nov; 38(8):1697-1704. PubMed ID: 36173344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status.
    Murphy SP; Ward JH; Piña IL; Felker GM; Butler J; Maisel AS; Meng X; Prescott MF; Solomon SD; Januzzi JL
    JACC Heart Fail; 2022 Dec; 10(12):976-988. PubMed ID: 36456072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection fraction.
    Xie B; Gao Q; Wang Y; Du J; He Y
    Am J Transl Res; 2024; 16(5):1935-1944. PubMed ID: 38883372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Left Ventricular Ejection Fraction and N-Terminal pro-B-type Natriuretic Peptide after Sacubitril/Valsartan for Predicting Outcomes in Patients with Heart Failure with Reduced Ejection Fraction.
    Fang CC; Jao YTFN
    Acta Cardiol Sin; 2023 Mar; 39(2):297-308. PubMed ID: 36911550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
    Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
    Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction.
    Liu LW; Wu PC; Chiu MY; Tu PF; Fang CC
    Acta Cardiol Sin; 2020 Mar; 36(2):125-132. PubMed ID: 32201463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients.
    Yang L; Zhang M; Hao Z; Wang N; Zhang M
    ESC Heart Fail; 2022 Aug; 9(4):2428-2434. PubMed ID: 35437929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
    Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study.
    Li X; Zuo C; Chen C; Tian D; Li J; Fan L; Li X; Lv Q
    Int J Cardiol; 2023 Jan; 371():244-251. PubMed ID: 36174825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/Valsartan in Heart Failure with Hypertension Patients: Real-World Experiences on Different Ages, Drug Doses, and Renal Functions.
    Guan Y; Li X; Li H; Ren J; Tang K; Zhang C; Gu Z; Li X; Lv Q; Bian X
    High Blood Press Cardiovasc Prev; 2023 Nov; 30(6):561-572. PubMed ID: 37979031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
    Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
    Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of high flow hemodialysis on the biomarker of myocardium injury and the cardiac function related records in uremia patients].
    Tang L; Deng X; Dai Q; Xiao H; Shu Y; Jiang M; Wei L; Wang L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Jun; 29(6):547-550. PubMed ID: 28625246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
    Chen F; Tian G; Bai X; Li J; Yuan Z
    Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
    Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
    ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
    Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
    J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.